Atr-101    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
75クッシング病2
81先天性副腎皮質酵素欠損症3

75. クッシング病 [臨床試験数:191,薬物数:172(DrugBank:48),標的遺伝子数:61,標的パスウェイ数:121
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 191 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002240-17-GB
(EUCTR)
16/05/201706/03/2017A Study of ATR-101 for the Treatment of Cushing’s SyndromeA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome endogenous Cushing’s syndrome
MedDRA version: 20.0;Level: SOC;Classification code 10014698;Term: Endocrine disorders;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Millendo Therapeutics, Inc.NULLNot Recruiting Female: yes
Male: yes
16Phase 2United States;United Kingdom
2NCT03053271
(ClinicalTrials.gov)
April 13, 20176/2/2017A Study of ATR-101 for the Treatment of Endogenous Cushing's SyndromeA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's SyndromeCushing SyndromeDrug: ATR-101;Drug: PlaceboMillendo Therapeutics US, Inc.NULLTerminated18 Years80 YearsAll4Phase 2United States;United Kingdom

81. 先天性副腎皮質酵素欠損症 [臨床試験数:65,薬物数:77(DrugBank:20),標的遺伝子数:11,標的パスウェイ数:65
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 65 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004878-34-FR
(EUCTR)
18/09/201824/04/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2
Millendo Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2France;Spain;Brazil;Israel
2EUCTR2017-004878-34-ES
(EUCTR)
01/08/201821/05/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2
Millendo Therapeutics US, Inc.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2France;Brazil;Spain;Israel
3NCT02804178
(ClinicalTrials.gov)
May 18, 20161/6/2016A Study of ATR-101 for the Treatment of Congenital Adrenal HyperplasiaA Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal HyperplasiaCongenital Adrenal HyperplasiaDrug: ATR-101Millendo Therapeutics, Inc.NULLCompleted18 Years80 YearsAll10Phase 2United States